Constructive Bio's Ola Wlodek on Commercialising the Expanded Genetic Code

In an exclusive conversation ahead of her appearance at SynBioBeta 2026 on May 4-7th in San Jose, Constructive Bio CEO Ola Wlodek made the case that the company has moved past proof of concept and into the harder work of converting recoded cells into a commercial pharmaceutical platform.

The Cambridge, UK-based company has raised $75 million to date, including a $58 million Series A closed fully in late 2025 led by Ahren Innovation Capital, OMX Ventures, and Paladin Capital Group, with Nobel laureate Sir Gregory Winter joining the board. Led by Wlodek and founded by MRC Laboratory of Molecular Biology professor Jason Chin, the company is built on two decades of work from the Chin Lab on whole-genome writing and engineered translation. That stack culminated in Syn61, an Escherichia coli strain whose genome was rewritten with more than eighteen thousand precise codon replacements to free up three sense codons for non-canonical amino acids.

Wlodek frames the underlying thesis in industrial rather than academic terms.

"Life is the most sophisticated manufacturing platform that has ever existed. It scales, it self-repairs, it runs on carbon and sunlight," she said. "The question was never whether it could work, it was how we could best apply it."

That framing animates the SynBioBeta main-stage panel she will join with Aralez Bio CEO Tina Boville and Antheia CEO Christina Smolke, moderated by GEN Deputy Editor in Chief Julianna LeMieux. The three companies operate in different niches but share a wager that fermentation can outcompete chemistry on cost, waste, and chemical complexity for high-value molecules. The reference point Wlodek often returns to is the GLP-1 class. Drugs like semaglutide are currently produced via solid-phase peptide synthesis, generating roughly fourteen thousand kilograms of chlorinated waste per kilogram of product. Constructive's pitch to pharma partners is that recoded organisms can manufacture these and far more complex peptides and proteins at industrial scale, with non-canonical amino acids placed at programmed positions for improved stability and efficacy.

Her near-term roadmap is unusually specific for a company at this stage. Three priorities, she said, are running in parallel.

The first is closing and delivering on long-term commercial partnerships. Engagements with pharma are already underway, and the goal is to convert technical maturity into deals that reflect what the platform can do. The second is delivering a next-generation recoded strain with improved robustness and scalability for industrial fermentation, a release the company expects soon. The third is publicising concrete applications of an expanded genetic code, the proof points she believes the field needs to silence the lingering scepticism around synthetic biology's commercial trajectory.

"We've raised $75 million to date, which gives us a strong runway to deliver on all of the above," Wlodek said. "The ambition beyond that is to bring in revenue from commercial partnerships rather than rely solely on venture capital, to grow as a business, not just as a technology."

That commercial discipline reflects what she described as growing impatience with the framing of synthetic biology as a disappointment. In her view, the science has matured, and the remaining question is whether founders can build the operating companies that translate it into revenue. Asked what has kept her in the field, she pointed to the same property that drew her in.

"What really drew me to synthetic biology, and keeps me here, is the materiality of the outputs and the power of iterative improvement, you build, you measure, you get better."

For investors and pharma business development teams gathering in San Jose, the substantive question Constructive Bio is putting on the table is whether a recoded cell can become a routine manufacturing chassis for the next generation of peptide and protein therapeutics. Wlodek's answer is that the platform is ready, the applications are underway, and the impact will follow.